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Abstract 
Objectives: The first objective was to determine the long-term retention rate of eight antiepileptic drugs (AEDs) 
commonly used as adjunctive therapy in adults with focal refractory epilepsy.  Secondly, we assessed the effects of age 
and gender on retention rates. Thirdly, we examined if the retention rate could be influenced by the sequence in which 
the AEDs had entered the market. 
Materials and methods: Patients with focal refractory epilepsy treated with any of the eight AEDs in Tampere University 
Hospital were identified retrospectively (N=507). Retention rates were evaluated with the Kaplan-Meier method. Follow-
up started at the first date of treatment and each individual was followed a maximum of 36 months.  
Results: We calculated the following three-year retention rates; lacosamide, 77.1% (N=137); lamotrigine, 68.3% 
(N=177); levetiracetam 66.7% (N=319), clobazam, 65.6% (N=130); topiramate, 61.6% (N=178); zonisamide, 60.4% 
(N=103); pregabalin, 54.6% (N=127); gabapentin, 40.2% (N=66). Lacosamide, levetiracetam and clobazam were the 
most effective AEDs in the elderly. The retention rate for pregabalin was higher in males (65%) than females (51%) 
whereas females had higher retention rates for both topiramate (72% vs. 58%) and zonisamide (67% vs. 57%). The 
retention rate was influenced by the sequence in which these AEDs entered the market. 
Conclusion: We provide important information about practical aspects of these eight AEDs, revealing that there are  
differences in their effectiveness as adjunctive treatment for focal refractory epilepsy. Most importantly, the retention rate 
appears to be influenced by the sequence in which these AEDs were introduced onto the market. 
This is an accepted manuscript. The original article has been published in Journal of 
Neurology. 2017, Vol. 264(7), pp. 1345–1353.  The final publication is available at 
Springer via http://dx.doi.org/10.1007/s00415-017-8526-8. 
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Introduction 
Epilepsy is a chronic disorder that often requires lifelong treatment with antiepileptic drugs (AEDs). During the last 
decade, a new AED has been introduced for clinical use almost on an annual basis. This makes it increasingly difficult 
for the clinician to make a rational choice about which AED to select for which patient, especially in patients with drug-
resistant epilepsy. It has been claimed that the choice of an AED is currently more empirical than evidence-based [1]. The 
tolerability and efficacy of new AEDs have been demonstrated in regulatory trials, but their strict entry and dosing criteria 
limit the amount of useful data that can be utilized in clinical practice [2]. 
 
Both the International League Against Epilepsy (ILAE) and the European Medicines Agency (EMEA) have emphasized 
the importance of gathering long-term retention data as a relevant endpoint for clinical trials of AEDs [3,4], since this 
provides information that can be applied readily to everyday practice [5]. The long-term retention rate of patients on their 
AED treatment is accepted as one of the clearest reflections of the drug’s true therapeutic effectiveness (i.e. it combines 
aspects of efficacy and tolerability) [6]. 
 
Firstly, we evaluated the long-term retention rates for eight of the most commonly used AEDs as adjunctive therapy in 
our institution in patients with focal refractory epilepsy: clobazam, gabapentin, lacosamide, lamotrigine, levetiracetam, 
pregabalin, topiramate and zonisamide. Brivaracetam and perampanel were excluded from the analysis because they were 
not licensed in Finland at the time of this analysis, eslicarbazepine acetate because it was not fully reimbursed, and 
carbamazepine, oxcarbazepine and sodium valproate because they are extensively administered as the first-line therapy 
for new onset epilepsy [7]. The poor long-term retention rate for tiagabine (38.2%) in our center had been determined 
earlier based on an analysis conducted in 2004 [8]; since then, tiagabine has not been prescribed in our institution and 
therefore it was excluded from the current study. Vigabatrin was included in the early phase of the analysis, but excluded 
from the final analysis due to low number of cases (N=37). 
 
Secondly, we assessed the effects of age and gender on retention rates of all eight AEDs due the fact that currently there 
is a lack of specific prescribing guidance for these subgroups of people with epilepsy [9]. 
 
It has been speculated, but not confirmed earlier, that the retention rate could be influenced by the sequence in which 
AEDs have been introduced into market [10]. Therefore, we analyzed each drug in terms of annual prescriptions and 
withdrawals from the introduction of the drug in Finland up to the final assessment point.  
 
Materials and methods 
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Patients with focal refractory epilepsy (age  18 years) treated in Tampere University Hospital from January 1, 2004, to 
December 30th, 2014 were identified from the hospital patient registry using ICD-10 diagnostic codes for focal and 
unclassifiable epilepsy (G40.1X, G40.2X and G40.9). Refractory epilepsy was defined as having seizures after trials of 
at least two AEDs with maximally tolerated doses either sequentially or in combination therapy. However, patients 
ranging from 4-16% demonstrate only one prior AED in Table 1. To clarify, prior AEDs are defined as priory initiated 
and tapered off due to inefficacy in Table 1. In patients with one prior AED, the second AED failed to achieve complete 
seizure freedom, but it was continued due to clinical reasons (i.e. partial effect on seizure duration or frequency) and third 
AED was initiated as a combination therapy with the second AED. We included patients with focal refractory epilepsy 
who had ever used at least one of the following AEDs: clobazam, gabapentin, lacosamide, lamotrigine, levetiracetam, 
pregabalin, topiramate or zonisamide, (N = 507). All patients started these AEDs as adjunctive therapy. Overall, 21.9 % 
of the patients were treated with monotherapy, 43.0% with duotherapy, 29.7% with triple therapy, and 5.4% were being 
administered four AEDs. We retrospectively reviewed patient background, medical history, current and previous AED 
use, duration of therapy and reasons for treatment discontinuation. The etiologies were classified into either known 
(structural, metabolic, infectious) or unknown etiologies [11]. The majority of the refractory patients in the Tampere 
University Hospital district (population of 505 000) are monitored in our clinic and only some elderly as well as those 
patients with moderate or severe mental retardation are treated elsewhere.  
 
The following classifications were made for the subgroup analyses. Age was categorized into two groups: <60 years of 
age and 60 years of age and the subjects were also subdivided by gender. 
 
The background and medical characteristics of the patients are reported as means and ranges or proportions. The Kaplan-
Meier method was used to obtain a product-limit estimate of the retention rate, and comparisons between the retention 
curves were analyzed using log-rank tests. Significance was determined as p < 0.05. Bonferroni correction was used for 
multiple comparisons. Follow-up started on the first date of treatment and each person was followed for a maximum of 
36 months. Follow-up lasted until discontinuation of the treatment (event), death, or the end of the follow-up (range from 
2 days to 36 months). All analyses were performed with Stata Statistical Software version 13.1. 
 
Results 
Clinical and demographic data on the patients treated with each AEDs are summarized in Table 1. Retention curves for 
all AEDs are presented in Figure 1. We estimated the following three-year retention rates; clobazam, 65.6%; gabapentin, 
40.2%; lacosamide, 77.1%; lamotrigine, 68.3%; levetiracetam, 66.7%; pregabalin, 54.6%; topiramate, 61.6%; 
zonisamide, 60.4% (Table 2). Log-rank test showed significant variation between the AEDs (p=0.0001). In pairwise 
comparison lacosamide (p=0.003), lamotrigine (p=0.01), and levetiracetam (p=0.04) retention was significantly increased 
compared to gabapentin after Bonferroni correction. Other statistically significant differences between the retention rates 
could not be identified in pairwise comparison. 
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The reasons for discontinuation by those patients who terminated a particular AED within the three year follow-up period 
are shown in Table 3. The results of the subgroup analyses in which the patients were categorized according either to age 
or gender are summarized in Table 4. The annual number of initiations and discontinuations for lacosamide, levetiracetam, 
pregabalin, topiramate and zonisamide used as an adjunctive therapy in focal refractory epilepsy from 1995 to 2014 are 
illustrated in Figure 2. 
 
Discussion 
The most crucial finding in our study was that the retention rate appeared to be influenced by the sequence in which these 
AEDs were introduced onto the market and this “latest drug phenomena” should be taken into account when assessing 
the effectiveness of AEDs. Furthermore, we calculated the following long-term retention rates; lacosamide 77%, 
lamotrigine 68%, levetiracetam 67%, clobazam 66%, topiramate 62%, zonisamide 60%, pregabalin 55% and gabapentin 
40%. All patients fulfilled the ILAE´s definition of pharmacoresistance [12].  
 
An ideal study design should be relevant to real-world settings and provide encompassing measures of efficacy and 
tolerability assessed with reliable and valid tools. This requirement is usually not fulfilled in regulatory trials, which focus 
on efficacy and dose response in refractory patients. Often in these clinical trials, the dosage range tends to be high, the 
titration schedule too rapid and the follow-up period very short. In contrast, the retention rate is considered to be a 
compound measure of drug efficacy, safety and compliance, ultimately expressing the willingness of patient to take the 
drug.  
 
It has been hypothesized that the retention rate can be influenced by the sequence in which these AEDs are introduced 
onto the market [10], but as far as we are aware, this has not been actually determined previously. In Finland, after 
authorities have given approval for full reimbursement, a new AED is made available free of charge for its licensed 
indication and the clinician can prescribe this drug to suitable patients. As shown in Figure 2, the use of a new AED 
significantly increases once full reimbursement is approved. Patients being administered AEDs that were marketed first 
could have discontinued that treatment after a new drug became available, as demonstrated in Figure 2. For example, 
topiramate entered the full reimbursement market in the year 2000; its peak of treatment discontinuations occurred in 
2005 when a new AED (levetiracetam) became available. Similarly in 2007; many patients receiving levetiracetam 
terminated its use because of the availability of new drug (pregabalin). Finally, the number of annual discontinuations for 
pregabalin increased in 2008 when yet another AED (zonisamide) received full reimbursement approval. At the time of 
analysis, lacosamide was the latest AED which had been awarded full reimbursement (2012) and the peak of withdrawals 
from this drug had still not been observed by the end of year 2014. Additionally, lacosamide could have been tested in a 
more drug resistant cohort of patients. Our results suggest that the retention rate appears to be influenced by the sequence 
in which these AEDs have been introduced onto the market. This “latest drug phenomena” should be taken into account 
in the long-term retention rate studies, when comparing the effectiveness of subsequently marketed AEDs. 
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In the subgroup analysis, the effects of age and gender on retention rates of all eight AEDs were studied. Despite the well-
known modifications in AED pharmacokinetics and pharmacodynamics in the elderly, we found only one retrospective, 
uncontrolled study of older patients (55 years) with epilepsy which would have evaluated effectiveness by comparing 
12-month retention rates of 10 different AED [9]. In our study, lacosamide was the most effective AED in the elderly as 
measured by its three year retention rate, followed by levetiracetam and clobazam. Zonisamide and gabapentin were the 
least effective drugs. Our results are similar to those of Arif et al. [9] with one exception. In our study, lamotrigine had 
the third lowest retention rate (63%) in contrast to that previous study, in which lamotrigine had the highest retention rate 
(79%). The differences might be explained by the limited number of patients receiving each AED in both studies. 
 
Surprisingly, very little is known about the effectiveness of AEDs between females and males in the light of long-term 
retention rate studies. We could not identify any study focusing on this topic. Three year retention rate for pregabalin was 
higher in males (62%) than females (53%) whereas females had a higher retention rate for both topiramate (70% vs. 56%) 
and zonisamide (68% vs. 57%). In fact, topiramate was the third best tolerated AED in females. However, results did not 
reach statistical significance due to limited number of patients. One might hypothesize that these results would reflect 
cosmetic side effects of AEDs to which females tend to be more prone, as pregabalin is associated with gaining weight 
whereas both topiramate and zonisamide might cause a loss of body weight [13].  
 
The highest retention rate was found for lacosamide (77%), which is exactly the same percent as in prospective audit with 
adjunctive lacosamide in focal uncontrolled epilepsy conducted in the Western Infirmary in Glasgow, Scotland [14]. In a 
large cohort with medically refractory epilepsy, the retention rate for lacosamide was 62% at one year, 45% at two years 
and 35% at three years [15]. This difference may be explained by the differences in study populations.  Novy et al. [15] 
conducted the study in a tertiary referral center in which each new assessment selects patients who did not respond to a 
number of previous AEDs (87% to at least six prior AEDs) i.e. the population is becoming increasingly refractory [5] in 
comparison to our study which was performed in a secondary epilepsy center. Furthermore, in our clinic, lacosamide is 
often used in the early phase as an adjunctive therapy with a low number of prior AEDs and this improved the possibility 
of its efficacy and thus higher retention. The discontinuation of the lacosamide has been mainly due to the adverse events 
(50%) rather than the drug’s lack of efficacy (19%). This finding is in line with most of earlier studies [14,16,17] but 
contrary to Novy et al. [15].  
 
Lamotrigine had the second highest long-term retention rate i.e. 68% which agrees well with the findings in the previous 
studies (69-74% at 2-3 years) [6,8,18]. Nonetheless, a study executed in a tertiary referral center found a significantly 
lower retention rate of 40% at three years [19]. Lamotrigine is known to be well tolerated [6,8] and this was the case also 
in our study.  
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Levetiracetam had the third highest retention rate at three years (67%). Other studies have reported similar outcomes 
[8,18,20], but one report found a poorer outcome i.e. a retention rate of 46% at two years [6]. In our study, adverse-events 
were the cause of discontinuation in only 34% of the cases suggesting that this drug has a favorable tolerability profile. 
 
The retention rate for clobazam was good: 66% of the patients continued the treatment for three years. There are very 
limited data on the long-term retention rate for clobazam treatment. Indeed, we found only one study (N = 54) which was 
conducted with highly refractory patients (mean of 8 previous AEDs) reporting a 12 month retention rate (61%) for 
clobazam [21]. In our audit, clobazam’s discontinuation of was equally often due to its adverse effects and its lack of 
efficacy. According to our results, clobazam can be considered a safe and effective AED. The good long-term retention 
rate also indicates that the tolerance issues related to adjunctive clobazam treatment might have been overestimated. 
 
Topiramate had a retention rate of 62% following closely behind clobazam. The majority of previous studies have reported 
significantly lower long-term retention rates between 30-50% for topiramate [6,18,19,22,23]. Perhaps this is attributable 
to  the  divergences  between the  study populations.  In  our  study,  as  in  previous  reports,  adverse  events  were  the  most  
prominent reason for discontinuation of topiramate treatment out of all of the evaluated eight AEDs. Our results imply 
that if the patient tolerates the acute toxic effects of topiramate then this is a good indicator of long-term retention, since 
most withdrawals occur within the first year. This fact has also been mentioned by other investigators [6,18,23]. 
 
The retention rate of zonisamide after 36 months as adjunctive therapy in adult patients with refractory focal epilepsy was 
60%. One Scandinavian study with a similar patient cohort to ours reported a 12 month retention rate of 54% for 
zonisamide [24]. Other studies have estimated 45-65% retention rates after 12 months’ zonisamide treatment [18,23,26]. 
One study with a large cohort from a tertiary epilepsy center reported a three year retention rate of 30% [27]. Here, the 
drug was fairly well tolerated, with only 30% of the subjects discontinuing therapy due to adverse events, in line with an 
earlier study [24]. In our study, the majority of those patients who discontinued because of tolerability problems, did so 
during the first 150 days after initiation of zonisamide therapy.  
 
Pregabalin appeared to be one of least well tolerated AEDs in our study with a retention rate of 55%. In recent years, 
almost all publications with pregabalin have been addressing different indications other than epilepsy. Surprisingly, we 
found only one report from a tertiary referral center which would have addressed the long-term outcome in a large group 
of patients. In this study with 402 patients, the estimated 2.5 year retention rate was 32% (26). In their prospective audit, 
Stephen et al. [28] showed that 50% of those patients treated with pregabalin remained on the drug whereas 46% 
discontinued the treatment due to adverse events, a similar number as noted here (41%). 
 
Gabapentin was the drug producing the greatest number of complexities leading to discontinuation, with a retention rate 
of only 40%, a value in line with one earlier report [8]. The data on long-term retention with gabapentin is very limited. 
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We found that 74% of discontinuations were due to a lack of efficacy and only 11% were attributable to adverse events. 
Our findings support the impression that gabapentin might be better tolerated than several other AED, but it seems to 
possess relatively limited efficacy. 
 
Direct comparison of the AEDs is difficult based on the nature of the current study, but it might be worthwhile noting the 
characteristics of the patients receiving different drugs. The number of patients on each AED was relatively high (over 
125 patients) with the exceptions of zonisamide (N = 103) and gabapentin (N = 66). Females and males were equally 
represented in all of the groups. The known etiology for focal seizures has been considered as a marker of 
pharmacoresistance [29]. The majority of the patients receiving levetiracetam, lamotrigine and zonisamide had a known 
etiology. The mean duration of epilepsy varied from 17 years (lacosamide) to 27 years (gabapentin and lamotrigine) 
highlighting the refractory nature of our patient cohort. The mean doses for all eight AEDs were mostly equal or 
marginally higher than the World Health Organization (WHO) defined daily doses, suggesting that the overall drug load 
was not excessive in our patients [30]. Finally, generally is known how much drug resistance is influenced by previous 
unsatisfactory treatments. As the majority of the patients on lamotrigine, topiramate, pregabalin, zonisamide, clobazam 
and gabapentin had previously tried a minimum of four AEDs, these cohorts must be characterized as being highly drug 
resistant. These observations might indicate that patients with a known etiology or/and high number of previous AEDs 
had more severe epilepsy which could have detrimentally influenced their long-term retention rate. On the other hand, 
percentage of patients who have previously taken more than 4 AEDs varies from almost 70% with gabapentin, to almost 
40% with lacosamide. Incidentally, lacosamide resulted the AED with the best retention rate. This data weaken the 
observation that lacosamide has a better retention. Overall, no major differences were found with respect to any of the 
demographical or clinical variables, which allows us to compare these eight AEDs and to hypothesize that differences in 
their long-term retention rates are drug-related. 
 
A variety of factors may have influenced these retention rates. The mean times to intolerability were in the range of 3.6 
(lamotrigine) to 10.2 months (gabapentin). This data might indicate that only a minority of the intolerable adverse events 
could have been due to rapid titration. Furthermore, if patients terminated treatment with one drug due to adverse events, 
this was most likely to occur during the first 12 months. This might indicate that if adverse events of an AED do not 
appear relatively early, they are unlikely to appear after years of treatment as observed in an earlier study [9]. The time 
to reach a conclusion about insufficient efficacy took somewhat longer, 9 – 13 months with most of the drugs, ranging 
from only seven months with lacosamide up to 16 months with clobazam. 
 
Some points must be kept in mind when drawing conclusions from this study. All patients were from a single center, 
which limits external validity of findings. Retrospective nature and the lack of available comparative data are the main 
disadvantages of retention rate analysis with the current study not being an exception. Furthermore, patients were not 
randomized to receive any particular AED. Quite likely, physician preference/bias played a role in drug selection and 
decisions to withdraw certain AED treatments, but no statistical method can remove or fully account this effect [9]. The 
lack of systematic titration data for AEDs is a limitation of study, as too rapid titration might have an effect on tolerability. 
 9 
 
For certain AEDs, the number of patients is relatively small, this is particularly true in the subgroup analysis of elderly 
patients. Therefore, it might be most appropriate to compare our results with those from other pragmatic studies evaluating 
retention with adjunctive AEDs in adult patients with refractory focal epilepsy. Even in those cases, the different 
methodologies and study populations may allow only indirect comparison. However, tolerability has been evaluated 
analogously in all studies i.e. the percentage of patients terminating drug treatment because of adverse events.  
 
In conclusion, the retention rate appears to be influenced by the sequence in which these AEDs were introduced onto the 
market. Our study provides important information of many practical aspects of the AED therapy and indicates that there 
are differences in effectiveness between clobazam, gabapentin, lacosamide, lamotrigine, levetiracetam, pregabalin, 
topiramate and zonisamide as adjunctive treatment for focal refractory epilepsy. Those AEDs that are modestly 
efficacious but associated with a good tolerability profile might perform better than drugs that are more efficacious with 
significant tolerability problems. The value of retention rate studies as a valuable information source for physicians is 
highlighted.   
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Table 1. Demographic and medical characteristics of the patients 
 Clobazam Lamotrigine Gabapentin Topiramate Levetiracetam Pregabalin Zonisamide Lacosamide 
Year of introduction onto the 
Finnish market 
1988 1994 1995 1999 2001 2004 2007 2009 
Date of full reimbursement 1.1.1990 1.7.1996 1.7.1996 1.9.2000 1.1.2005 1.7.2007 1.11.2008 1.1.2012 
N 130 177 66 178 319 127 103 137 
Sex         
  Female (%) 48.5 55.4 54.5 48.3 49.8 51.2 49.5 51.1 
  Male (%) 51.5 44.6 45.5 51.7 50.2 48.8 50.5 48.9 
Etiology         
  Known (%) 29.6 58.7 30.0 34.2 66.5 37.8 56.3 33.5 
  Unknown (%) 70.4 41.3 70.0 65.8 33.5 62.2 43.7 66.5 
Duration of epilepsy (years)         
  Mean 20.7 27.1 27.3 23.5 20.2 25.4 23.5 16.6 
  Range 0-72 1-72 2-63 0-72 0-70 2-70 2-63 0-63 
Age         
  Mean 44.6 48.1 51.7 49.2 50.6 46.4 42.7 54.0 
  Range 19-85 19-85 24-85 20-85 19-85 19-85 19-76 21-85 
Number of prior AEDs*         
  1 (%) 11.8 8.9 4.5 7.9 16.3 7.4 4.9 16.3 
  2 (%) 15.0 14.8 7.6 14.7 21.5 9.2 7.8 18.8 
  3 (%) 17.4 17.5 18.2 18.4 20.6 17.6 21.3 25.2 
   4 (%) 55.8 58.8 69.7 59.0 41.6 65.8 66.0 39.7 
AED = Antiepileptic drug 
* = Defined as initiated and withdrawn due to inefficacy 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Mean duration (months) of treatment and mean dose (mg per day) of AEDs for all patients, patients who discontinued the drug, and for those who continued the 
treatment 
 All patients Discontinued On medication 3-year retention rate 
  Duration Dose  Duration Dose  Duration Dose 
 n Mean (range) Mean (range) n Mean (range) Mean (range) n Mean (range) Mean (range) % 95% CI 
Levetiracetam 319 23.4 (0-36) 2001 (100-3500) 138 15.5 (0-36) 2271 (250-3500) 181 29.3 (0-36) 1800 (100-3500) 66.7 61.0 to 71.8 
Lamotrigine 177 26.1 (0-36) 305 (25-800) 71 16.5 (0-36) 297 (50-800) 106 32.6 (0-36) 310 (25-550) 68.3 60.6 to 74.7 
Topiramate 178 24.8 (0-36) 326 (30-1600) 97 19.5 (1-36) 338 (30-1600) 81 31.2 (0-36) 311 (50-600) 61.6 53.8 to 68.5 
Pregabalin 127 22.8 (0-36) 415 (25-600) 62 12.1 (0-36) 415 (25-600) 65 33.0 (10-36) 415 (75-600) 54.6 45.4 to 63.0 
Zonisamide 103 21.1 (0-36) 354 (25-600) 39 9.9 (0-36) 349 (25-600) 64 27.9 (1-36) 356 (200-600) 60.4 49.5 to 69.6 
Clobazam 130 22.4 (0-36) 21.8 (2-200) 50 17.1 (0-36) 23.6 (2-200) 80 25.7 (0-36) 20.7 (5-80) 65.6 55.7 to 73.8 
Lacosamide 137 16.9 (0-36) 396 (100-600) 28 7.7 (0-36) 363 (200-600) 109 19.2 (0-36) 405 (100-600) 77.1 67.8 to 84.0 
Gabapentin 66 20.8 (1-36) 2692 (900-4800) 55 19.5 (1-36) 2804 (900-4800) 11 27.5 (6-36) 2136 (900-3600) 40.2 28.1 to 52.0 
 
Missing information: 
 Dose of levetiracetam, 3 patients (discontinued) 
 Dose of lamotrigine, 4 patients (discontinued)  
 Dose of topiramate, 2 patients (discontinued) 
 Dose of pregabalin, 1 patient (discontinued) 
 Dose of clobazam, 1 patient (discontinued) 
 
 
 
 
 
 Table 3. Reason for discontinuation of one of the tested antiepileptic drug and mean duration (months) of treatment in subjects who discontinued the drug 
 
 Discontinued    Lack of efficacy        Adverse effect   Lack of efficacy and adverse effect                    Other reason 
          n n           % Duration   n        %   Duration               n                  %       Duration                n            %      Duration 
Clobazam         38 16      42.1   15.6  14     36.8        5.9               2                 5.3          14.6                6          15.8        13.8 
Gabapentin         38 28      73.8   12.5  4      10.5       10.2               4                10.5         13.3                2           5.2           2.1 
Lacosamide         26 5        19.2   7.3 13     50.0        4.7               2                 7.7           6.0                6          23.0          2.9 
Lamotrigine         54 29      53.7   12.0 17     31.5        3.6               3                  5.6           7.5                5           9.3          12.8 
Levetiracetam        100 49      49.0   8.6 34     34.0        5.9               8                  8.0          12.4                 9           9.0           5.7 
Pregabalin         56 22      39.3   8.9 23     41.0        9.0               9                16.1         10.8                2           3.6          17.1 
Topiramate         65 16      24.6   12.7 34     52.3        9.1              10              15.4         17.7                5           7.7           9.8 
Zonisamide         37 17      46.0   9.6 11     29.7        5.6               7               16.2          8.2                3            8.1           1.0 
 
 
 
 
 
 
 
 
 
Table 4. The effect of age and gender on retention rates of the eight antiepileptic drugs 
  Three year retention rate  
 Age (years)  Gender  
 < 60  60 p Female Male p 
Clobazam 68.0 73.9 0.57 68.0 70.0 0.98 
Gabapentin 43.7 47.7 0.68 45.6 44.4 0.77 
Lacosamide 76.7 80.0 0.93 80.6 74.0 0.64 
Lamotrigine 67.0 61.4 0.56 66.1 64.6 0.84 
Levetiracetam 71.6 74.5 0.67 72.6 72.1 0.98 
Pregabalin 53.7 71.9 0.12 53.2 62.2 0.45 
Topiramate 61.0 68.6 0.30 69.8 56.3 0.085 
Zonisamide 64.8 50.8 0.35 68.2 57.2 0.24 
 
 
 
 
Figure 1. Retention rates for clobazam, gabapentin, lacosamide, lamotrigine, levetiracetam, pregabalin, topiramate, and zonisamide in patients with focal epilepsy by Kaplan-
Meier analysis  
 
Figure
Figure 2. The number of annual initiations (curves, right column) and discontinuations (bars, left column) for antiepileptic drugs used as an adjunctive therapy in focal 
refractory epilepsy from 2000 to 2014. The location of color code indicates the year of full reimbursement for each antiepileptic drug in Finland  
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